These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30388910)

  • 1. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
    Booth L; Roberts JL; Spiegel S; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):597-607. PubMed ID: 30388910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.
    Hwang KE; Kim YS; Jung JW; Kwon SJ; Park DS; Cha BK; Oh SH; Yoon KH; Jeong ET; Kim HR
    Oncotarget; 2015 Oct; 6(30):29482-96. PubMed ID: 26334320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.
    Booth L; Roberts JL; Poklepovic A; Gordon S; Dent P
    Oncotarget; 2017 Jan; 8(1):1449-1468. PubMed ID: 27903966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
    Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
    Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Chuckalovcak J; Stringer DK; Koromilas AE; Boone DL; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(17):23608-32. PubMed ID: 27015562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Cancer Biol Ther; 2017 Sep; 18(9):705-714. PubMed ID: 28812434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential regulation of autophagy and cell viability by ceramide species.
    Cruickshanks N; Roberts JL; Bareford MD; Tavallai M; Poklepovic A; Booth L; Spiegel S; Dent P
    Cancer Biol Ther; 2015; 16(5):733-42. PubMed ID: 25803131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
    Ota K; Okuma T; Lorenzo A; Yokota A; Hino H; Kazama H; Moriya S; Takano N; Hiramoto M; Miyazawa K
    Oncol Rep; 2019 Jul; 42(1):231-242. PubMed ID: 31059070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
    Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS
    Cells; 2019 Nov; 8(12):. PubMed ID: 31795298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy.
    Jiang X; Lu W; Shen X; Wang Q; Lv J; Liu M; Cheng F; Zhao Z; Pang X
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells.
    Booth L; Poklepovic A; Hancock JF; Dent P
    Anticancer Drugs; 2023 Oct; 34(9):1025-1034. PubMed ID: 37703296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
    Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
    BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
    BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.
    Choi MK; Ahn JS; Kim YC; Cho BC; Oh IJ; Kim SW; Lee JS; Kim JH; Ahn MJ; Park K
    Lung Cancer; 2018 May; 119():36-41. PubMed ID: 29656750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
    Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
    Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.